Mesalazine is an aminosalicylate drug used to treat mild to moderate active ulcerative colitis and also to maintain remission once achieved.

Brand Names
Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon
Generic Name
DrugBank Accession Number

An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease 2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent 1. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules 1. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.1,2

Small Molecule
Average: 153.1354
Monoisotopic: 153.042593095
Chemical Formula
  • 3-carboxy-4-hydroxyaniline
  • 5-aminosalicylic acid
  • 5-ASA
  • m-Aminosalicylic acid
  • Mesalamine
  • Mesalazina
  • Mésalazine
  • Mesalazine
  • Mesalazinum
  • p-Aminosalicylsaeure
External IDs
  • MAX-002
  • SPD476



Mesalazine is indicated for the treatment of mildly to moderately active ulcerative colitis in adults and patients 5 years or older.7,6. Mesalazine is also indicated for the maintenance of remission of ulcerative colitis in adults and maintenance of remission of Crohn's ileocolitis.8,3

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more

Mesalazine is one of the two components of sulphasalazine, the other being sulphapyridine. It is the latter which is responsible for the majority of the side effects associated with sulphasalazine therapy whilst mesalazine is known to be the active moiety in the treatment of ulcerative colitis 3.

The pharmacodynamic actions of mesalazine occur in the colonic/rectal mucosae local to the delivery of drug from mesalazine tablets into the lumen Label. There is information suggesting that the severity of colonic inflammation in ulcerative colitis patients treated with mesalazine is inversely correlated with mucosal concentrations of mesalazine Label. Plasma concentrations representing systemically absorbed mesalazine are not believed to contribute extensively to efficacy Label.

Mechanism of action

Although the mechanism of action of mesalazine is not fully understood, it is believed to possess a topical anti-inflammatory effect on colonic epithelial cells Label. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon Label.

Furthermore, mesalazine also has the potential to inhibit the activation of Nuclear Factor kappa B (NKkB) and consequently the production of key of pro-inflammatory cytokines Label. It has been proposed that reduced expression of PPAR gamma nuclear receptors (gamma form of peroxisome proliferator-activated receptors) may be implicated in ulcerative colitis Label. There is evidence that mesalazine produces pharmacodynamic effects through direct activation of PPAR gamma receptors in the colonic/rectal epithelium as well Label.

Moreover, since increased leukocyte migration, abnormal cytokine production, increased production of arachidonic acid metabolites, particularly leukotriene B4, and increased free radical formation in the inflamed intestinal tissue are all present in patients with inflammatory bowel disease it is also believed that mesalazine has in-vitro and in-vivo pharmacological effects that inhibit leukocyte chemotaxis, decrease cytokine and leukotriene production and scavenge for free radicals 4.

AProstaglandin G/H synthase 2
AProstaglandin G/H synthase 1
AArachidonate 5-lipoxygenase
APeroxisome proliferator-activated receptor gamma
UInhibitor of nuclear factor kappa-B kinase subunit alpha
UInhibitor of nuclear factor kappa-B kinase subunit beta
UMyeloperoxidaseNot AvailableHumans

Depending on the formulation administered, prescribing information for orally administered delayed-released tablets of 2.4g or 4.8g of mesalazine given once daily for 14 days to healthy volunteers was to found to be about 21% to 22% of the administered dose Label while prescribing information for an orally administered controlled-release capsule formulation suggests 20% to 30% of the mesalazine in the formulation is absorbed 17. In contrast, when mesalamine is administered orally as an unformulated 1-g aqueous suspension, mesalazine is approximately 80% absorbed 17.

Volume of distribution

For the extended-release formulation, mesalazine has a Vd of 18 L, confirming minimal extravascular penetration of systemically available drug.9 For the delayed-release formulation, the apparent volume of distribution was estimated to be 4.8 L.10

Protein binding

In an in vitro study, at 2.5 mcg/mL, mesalamine and N-Ac-5-ASA are 43±6% and 78±1% bound, respectively, to plasma proteins. Protein binding of N-Ac-5-ASA does not appear to be concentration dependent at concentrations ranging from 1 to 10 mcg/mL.8


Mesalazine is metabolized both pre-systemically by the intestinal mucosa and systemically in the liver to N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA) principally by NAT-1. Some acetylation also occurs through the action of colonic bacteria.4,8

Hover over products below to view reaction partners

Route of elimination

Elimination of mesalazine is mainly via the renal route following metabolism to N-acetyl-5-aminosalicylic acid (acetylation) Label. However, there is also limited excretion of the parent mesalazine drug in the urine Label.

After the oral administration of the extended-release formulation of mesalazine, of the approximately 21% to 22% of the drug absorbed, less than 8% of the dose was excreted unchanged in the urine after 24 hours, compared with greater than 13% for N-acetyl-5-aminosalicylic acid Label.

When given the controlled-release formulation, about 130 mg free mesalazine was recovered in the feces following a single 1-g dose, which was comparable to the 140 mg of mesalazine recovered from the molar equivalent sulfasalazine tablet dose of 2.5 g F3001]. Elimination of free mesalazine and salicylates in feces increased proportionately with the dose given. N-acetylmesalazine was the primary compound excreted in the urine (19% to 30%) following the controlled-release dosing 17.


For the delayed-release formulation, after intravenous administration, the elimination half-life of mesalamine is reported to be approximately 40 minutes. After oral dosing, the median terminal t1/2 values for mesalamine are usually about 25 hours, but are variable, ranging from 1.5 to 296 hours. There is a large inter-subject and intra-subject variability in the plasma concentrations of mesalamine and N-acetyl-5-aminosalicylic acid and in their terminal half-lives following the administration of mesalazine.6 For the extended-release formulation, following single and multiple doses of mesalazine, the mean half-lives were 9 to 10 hours for 5-ASA, and 12 to 14 hours for N-Ac-5-ASA.8


The mean (SD) renal clearance in L/h for mesalazine following the single dose administration of mesalazine delayed-release tablets 4.8g under fasting conditions to young and elderly subjects was documented as 2.05 (1.33) in young subjects aged 18 to 35 years old, 2.04 (1.16) in elderly subjects aged 65 to 75 years old, and 2.13 (1.20) in elderly subjects older than 75 years Label.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more

There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalazine absorption from the colon is limited. Although there is little to no clinical experience with mesalazine overdosage Label. Mesalazine is an aminosalicylate, and symptoms of salicylate toxicity may be possible, such as tinnitus, vertigo, headache, confusion, drowsiness, sweating, hyperventilation, vomiting, and diarrhea Label. Severe intoxication with salicylates can lead to disruption of electrolyte balance and blood-pH, hyperthermia, and dehydration Label.

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirMesalazine may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Abciximab.
AcarboseMesalazine may increase the hypoglycemic activities of Acarbose.
AcebutololMesalazine may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Mesalazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Acetazolamide.
AcetohexamideMesalazine may increase the hypoglycemic activities of Acetohexamide.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with or without food. The absorption is unaffected by food.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
International/Other Brands
Asacolitin / Claversal / Fisalamine / Iialda / Lixacol
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
5-asaTablet, delayed release400 mgOralSanis Health Inc2010-11-022012-08-03Canada flag
AprisoCapsule, extended release375 mg/1OralPhysicians Total Care, Inc.2010-08-18Not applicableUS flag
AprisoCapsule, extended release375 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-10-31Not applicableUS flag
AprisoCapsule, extended release375 mg/1OralSalix Pharmaceuticals, Inc.2008-10-31Not applicableUS flag
AsacolTablet400 mg/1OralRemedy Repack2010-08-102012-02-16US flag
AsacolTablet, delayed release400 mg/1OralAllergan1992-04-012015-06-30US flag
AsacolTablet, delayed release400 mg/1OralKAISER FOUNDATION HOSPITALS2012-02-232014-03-31US flag
AsacolTablet, delayed release400 mg/1OralAmerincan Health Packaging2012-01-232012-02-29US flag
AsacolTablet, delayed release400 mg/1OralAllergan, Inc.1992-04-012015-06-30US flag
AsacolTablet, delayed release400 mgOralAllergan1993-12-312020-07-17Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MesalamineTablet, delayed release1.2 g/1OralAvKARE2019-09-18Not applicableUS flag
MesalamineTablet, delayed release800 mg/1OralAmerican Health Packaging2019-04-17Not applicableUS flag
MesalamineTablet, delayed release1.2 g/1OralActavis Pharma, Inc.2018-03-26Not applicableUS flag
MesalamineTablet, delayed release1.2 g/1OralGolden State Medical Supply, Inc.2019-01-25Not applicableUS flag
MesalamineSuspension4 g/60mLRectalTeva2004-09-302013-01-31US flag
MesalamineTablet, delayed release1.2 g/1OralZydus Pharmaceuticals USA Inc.2017-06-19Not applicableUS flag
MesalamineCapsule, extended release0.375 g/1OralZydus Pharmaceuticals (USA) Inc.2021-08-13Not applicableUS flag
MesalamineTablet, delayed release800 mg/1OralZydus Pharmaceuticals (USA) Inc.2018-08-02Not applicableUS flag
MesalamineEnema; Kit4 g/60mLRectalPadagis Israel Pharmaceuticals Ltd2018-08-02Not applicableUS flag
MesalamineEnema; Kit4 g/60mLRectalbryant ranch prepack2009-09-01Not applicableUS flag


ATC Codes
A07EC02 — Mesalazine
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
Organic compounds
Super Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzoic acids
Alternative Parents
Salicylic acids / Benzoic acids / p-Aminophenols / Benzoyl derivatives / Aniline and substituted anilines / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids
show 5 more
1-hydroxy-2-unsubstituted benzenoid / Amine / Amino acid / Amino acid or derivatives / Aminobenzoic acid / Aminophenol / Aniline or substituted anilines / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid, phenols, aromatic amine, amino acid, monohydroxybenzoic acid (CHEBI:6775)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key
5-amino-2-hydroxybenzoic acid


Synthesis Reference

Thomas M. Parkinson, Joseph P. Brown, Robert E. Wingard, Jr., "Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract." U.S. Patent US4298595, issued January, 1975.

General References
  1. Mayberry J: The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013 Dec;22(4):375-7. [Article]
  2. Stolfi C, De Simone V, Pallone F, Monteleone G: Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci. 2013 Sep 3;14(9):17972-85. doi: 10.3390/ijms140917972. [Article]
  3. Electronic Medicines Compendium: Asacol (mesalazine) 400mg MR Tablets Monograph [Link]
  4. Electronic Medicines Compendium: Pentasa (Mesalazine) Sachet 2g Monograph [Link]
  5. FDA Approved Drug Products: Asacol HD (mesalamine) delayed-release tablets for oral use [Link]
  6. FDA Approved Drug Products: Delzicol (mesalamine) delayed-release capsules for oral use [Link]
  7. FDA Approved Drug Products: Canasa (mesalamine) suppositories for rectal use [Link]
  8. FDA Approved Drug Products: APRISO® (mesalamine) extended-release capsules [Link]
  9. Electronic Medicines Compendium: Mezavant XL 1200mg, gastro-resistant, prolonged release tablets [Link]
  10. Clinical Pharmacology Review : Asacol HD [Link]
  11. Mesalazine MSDS Pharmacopoeia [Link]
  12. Mesalazine MSDS Allergan [Link]
  13. Mesalazine MSDS USP [Link]
  14. FDA Approved Drug Products: LIALDA (mesalamine) delayed-release tablets, for oral use [Link]
  15. FDA Approved Drug Products: ROWASA (mesalamine) Rectal Suspension Enema [Link]
  16. Product Monograph: SALOFALK (mesalamine) delayed release tablets, for oral use [Link]
  17. Pentasa (Mesalazine) FDA Label [File]
Human Metabolome Database
PubChem Compound
PubChem Substance
Therapeutic Targets Database
Guide to Pharmacology
GtP Drug Page
RxList Drug Page
PDRhealth Drug Page
FDA label
Download (1.61 MB)
Download (67.7 KB)

Clinical Trials

Clinical Trials
4CompletedDiagnosticUlcerative Colitis1
4CompletedPreventionUlcerative Colitis1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Immune System Diseases / Lentivirus Infections / Sexually Transmitted Disease (STD)1
4CompletedTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis1
4CompletedTreatmentDiverticular Disease of the Colon1
4CompletedTreatmentIrritable Bowel Syndrome With Diarrhoea1
4CompletedTreatmentMild to Moderate Ulcerative Colitis1
4CompletedTreatmentUlcerative Colitis4
4Not Yet RecruitingTreatmentBiologics / Mesalazine / Self Efficacy / Ulcerative Colitis1
4Not Yet RecruitingTreatmentChildren / Exclusive Enteral Nutrition / Ulcerative Colitis1


  • Salix pharmaceuticals inc
  • Shire development inc
  • Perrigo israel pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Alaven pharmaceutical llc
  • Axcan pharma us inc
  • Warner chilcott pharmaceuticals inc
  • Alaven Pharmaceutical
  • Amerisource Health Services Corp.
  • Anip Acquisition Co.
  • Atlantic Biologicals Corporation
  • Axcan Pharma Inc.
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Cosmo SPA
  • Dept Health Central Pharmacy
  • Diversified Healthcare Services Inc.
  • Ferring Pharmaceuticals Inc.
  • Franklin Pharmaceutical LLC
  • Gavis Pharmaceuticals LLC
  • Heartland Repack Services LLC
  • Infar SA
  • Letco Medical Inc.
  • Norwich Pharmaceuticals Inc.
  • Paddock Labs
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Physicians Total Care Inc.
  • Prasco Labs
  • Prepak Systems Inc.
  • Resource Optimization and Innovation LLC
  • Salix Pharmaceuticals
  • Sanofi-Aventis Inc.
  • Shire Inc.
  • Solvay Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Vangard Labs Inc.
  • Warner Chilcott Co. Inc.
  • WC Pharmaceuticals
  • Wellspring Pharmaceutical
Dosage Forms
Capsule, extended releaseOral375 mg/1
Capsule, delayed releaseOral400 MG
Granule, for suspensionRectal2 G
SuspensionRectal2 G/50ML
SuspensionRectal4 G/50ML
TabletOral400 mg/1
Tablet, delayed releaseOral400 mg/1
Tablet, delayed releaseOral
Tablet, delayed releaseOral800 mg/1
Tablet, coatedOral400 mg
Tablet, coatedOral800 mg
Aerosol, foamRectal2 G
Aerosol, foamRectal4 G
EnemaRectal2 G
EnemaRectal4 G
GelRectal500 MG
Granule, for suspensionRectal1.5 G
SuppositoryRectal400 MG
TabletOral400 MG
TabletOral800 MG
Tablet, delayed releaseOral1000 mg
SuppositoryRectal1000 mg/1
SuppositoryRectal0.5 g
SuspensionRectal4 g
SuspensionRectal2 g
SuspensionRectal4 G/60G
Tablet, film coatedOral500 mg
Capsule, delayed releaseOral400 mg/1
Tablet, coatedOral
Tablet, delayed releaseOral1.2 g/1
SuspensionRectal6.67 g
Tablet, coatedOral500 mg
Tablet, delayed releaseOral400 mg
SolutionRectal2 G
SolutionRectal4 G
Granule, delayed releaseOral1000 mg
Granule, delayed releaseOral1500 mg
Granule, delayed releaseOral3000 mg
Granule, delayed releaseOral500 mg
Capsule, extended releaseOral0.375 g/1
Capsule, extended releaseOral500 mg/1
Enema; kitRectal4 g/60mL
PowderNot applicable1 g/1g
SuspensionRectal4 g/60mL
Aerosol, foamRectal
CapsuleOral400 MG
GelRectal2 G/60ML
GelRectal4 G/60ML
GelRectal10 %
Tablet, extended releaseOral1200 MG
SuspensionRectal7 g
Tablet, delayed releaseOral800 mg
SuspensionRectal6667 mg
Tablet, coatedOral505 mg
Tablet, extended releaseOral1.2 g
Tablet, delayed releaseOral1200 mg
Tablet, film coated, extended releaseOral
Tablet, delayed releaseOral1200.0 mg
KitRectal1 g / act
SuspensionRectal4 G/100ML
TabletOral1200 MG
CapsuleOral250 mg/1
CapsuleOral500 mg/1
SuspensionRectal1 g / 100 mL
SuspensionRectal1 G/100ML
SuspensionRectal2 G/100ML
SuspensionRectal4 g / 100 mL
TabletOral250 MG
Tablet, extended releaseOral1 g
EnemaRectal1 g
EnemaRectal1 g/100ml
Granule, delayed releaseOral
SuppositoryRectal1.000 MG
SuspensionRectal1000 MG
Enema; liquidRectal2 g / 100 mL
Tablet, extended releaseOral250 mg
SuspensionRectal1 g/100 ml
Granule, delayed releaseOral1 g
Granule, delayed releaseOral2000 mg
Granule, delayed releaseOral4000 mg
Tablet, extended releaseOral1000 mg
Tablet, extended releaseOral
TabletOral1000 mg
TabletOral500 mg
SuspensionRectal0.01 g/ml
GranuleOral1 g
TabletOral1 g
GranuleOral2 g
GranuleOral4 g
Granule, delayed releaseOral4 G
SuppositoryRectal1 g
SuppositoryRectal1000 mg
Granule, delayed releaseOral2 G
SuspensionRectal1 g
GranuleOral2000 mg
GranuleOral1000 mg
EnemaRectal4 g/60mL
GranuleOral1500 MG
SuspensionRectal2 g / 60 g
SuspensionRectal4 g / 60 g
EmulsionRectal1 g
GranuleOral3000 mg
Aerosol, foamRectal1 g
GranuleOral1.5 g
Granule, delayed releaseOral1.5 g
Tablet, delayed releaseOral1 G
SuppositoryRectal250 mg
Tablet, delayed releaseOral250 mg
Tablet, coatedOral250 mg
SuspensionRectal2 G/30ML
GranuleOral3 g
Granule, delayed releaseOral3 g
Tablet, delayed releaseOral500 mg
SuppositoryRectal500 mg
GranuleOral500 mg
GranuleOral500 mg/1sachet
TabletOral1600 MG
Tablet, delayed releaseOral1600 mg
Tablet, extended releaseOral500 mg
Unit descriptionCostUnit
Canasa 30 1000 mg Suppository Box488.32USD box
Canasa 1000 mg suppository13.88USD suppository
Salofalk (4 g/60 g) 4 g/enm Enema6.73USD enema
Canasa 500 mg suppository6.24USD suppository
Pentasa (4 g/100 Ml) 4 g/enm Enema5.02USD enema
Pentasa (1 g/100Ml) 1 g/enm Enema4.17USD enema
Salofalk (2 g/60 g) 2 g/enm Enema3.96USD enema
Asacol hd dr 800 mg tablet3.88USD tablet
Pentasa 500 mg capsule2.66USD capsule
Asacol 400 mg Enteric Coated Tabs2.22USD tab
Asacol ec 400 mg tablet1.94USD tablet
Salofalk 1000 mg Suppository1.81USD suppository
Pentasa 1 g Suppository1.8USD suppository
Salofalk 500 mg Suppository1.23USD suppository
Asacol 800 800 mg Enteric-Coated Tablet1.14USD tablet
Pentasa 250 mg capsule1.07USD capsule
Mesasal 500 mg Enteric-Coated Tablet0.69USD tablet
Pentasa 500 mg Sustained-Release Tablet0.63USD tablet
Asacol 400 mg Enteric-Coated Tablet0.59USD tablet
Salofalk 500 mg Enteric-Coated Tablet0.56USD tablet
Novo-5 Asa 400 mg Enteric-Coated Tablet0.42USD tablet
Rowasa 4 gm/60 ml enema0.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5541170No1996-07-302013-07-30US flag
CA2444814No2009-06-092021-10-24Canada flag
CA2111697No2002-08-202012-06-16Canada flag
US7645801No2010-01-122027-07-24US flag
US6773720No2004-08-102020-06-08US flag
US8436051No2013-05-072028-06-06US flag
US8217083No2012-07-102028-06-06US flag
US6893662No2005-05-172021-11-15US flag
US8580302No2013-11-122021-11-15US flag
US9089492No2015-07-282021-11-15US flag
US8911778No2014-12-162018-04-20US flag
US6551620No2003-04-222018-04-20US flag
US8337886No2012-12-252018-04-20US flag
US8865688No2014-10-212030-05-01US flag
US8496965No2013-07-302018-04-20US flag
US8940328No2015-01-272018-04-20US flag
US8956647No2015-02-172018-04-20US flag
US6649180No2003-11-182020-04-13US flag


Experimental Properties
melting point (°C)260-280 °CL44306
water solubility0.84 g/L at 20°CL44296
logP1.2Not Available
Predicted Properties
Water Solubility12.2 mg/mLALOGPS
pKa (Strongest Acidic)2.02Chemaxon
pKa (Strongest Basic)5.87Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area83.55 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity40 m3·mol-1Chemaxon
Polarizability14.26 Å3Chemaxon
Number of Rings1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Human Intestinal Absorption+0.9471
Blood Brain Barrier-0.6168
Caco-2 permeable-0.8829
P-glycoprotein substrateNon-substrate0.8186
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9912
Renal organic cation transporterNon-inhibitor0.9314
CYP450 2C9 substrateNon-substrate0.8284
CYP450 2D6 substrateNon-substrate0.8331
CYP450 3A4 substrateNon-substrate0.7636
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8712
CYP450 2D6 inhibitorNon-inhibitor0.9744
CYP450 2C19 inhibitorInhibitor0.6752
CYP450 3A4 inhibitorNon-inhibitor0.6628
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9023
Ames testNon AMES toxic0.9132
BiodegradationReady biodegradable0.6197
Rat acute toxicity1.7065 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9759
hERG inhibition (predictor II)Non-inhibitor0.9715
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Download (8.48 KB)
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f79-0900000000-db75ae2d436dd6156c91


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Pharmacological action
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
Uniprot ID
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [Article]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [Article]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [Article]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [Article]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [Article]
Pharmacological action
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
Uniprot ID
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
  1. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [Article]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Pharmacological action
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
Uniprot ID
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [Article]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [Article]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [Article]
Pharmacological action
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
Uniprot ID
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11. [Article]
  2. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9. [Article]
  3. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [Article]
  4. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [Article]
Pharmacological action
General Function
Scaffold protein binding
Specific Function
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or oth...
Gene Name
Uniprot ID
Uniprot Name
Inhibitor of nuclear factor kappa-B kinase subunit alpha
Molecular Weight
84638.88 Da
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [Article]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [Article]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [Article]
Pharmacological action
General Function
Scaffold protein binding
Specific Function
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or oth...
Gene Name
Uniprot ID
Uniprot Name
Inhibitor of nuclear factor kappa-B kinase subunit beta
Molecular Weight
86563.245 Da
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [Article]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [Article]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [Article]
Pharmacological action
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
Uniprot ID
Uniprot Name
Molecular Weight
83867.71 Da
  1. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [Article]


Pharmacological action
General Function
Arylamine n-acetyltransferase activity
Specific Function
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivat...
Gene Name
Uniprot ID
Uniprot Name
Arylamine N-acetyltransferase 1
Molecular Weight
33898.445 Da
  1. Mesalazine FDA Label [File]

Drug created at June 13, 2005 13:24 / Updated at December 07, 2022 21:30